Looking deeper

business deal investigation investigate magnifying glass review
The ACCC is investigating whether the proposed merger of Arrow and Apotex – two of the largest suppliers of generics in Australia – will impact on competition In early May, Arrow and Apotex announced a proposed merger of their Australian and New Zealand generic pharmaceutical and OTC operations. The Australian Competition and Consumer Commission (ACCC)

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous How can Australia stop the opioid epidemic before it's too late?
Next Research Roundup